Literature DB >> 21352847

Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat.

Valérie Bertaina-Anglade1, Christophe Drieu-La-Rochelle, Elisabeth Mocaër, Laure Seguin.   

Abstract

The aim of the present study was to evaluate the effects of agomelatine, an antidepressant with melatonergic agonist and 5-HT(2C) antagonist properties, in the rat novel object recognition (NOR) task, a model of short-term episodic memory. To assess the potential involvement of its chronobiotic activity, single intraperitoneal administration of agomelatine and NOR testing were performed either in the evening or in the morning. In both conditions, using a 24h retention interval, vehicle-treated rats did not discriminate between the novel and the familiar object (recognition index was not different from chance performance) while object memory performance of rats treated with agomelatine either in the evening (10 and 40mg/kg) or in the morning (2.5, 10, and 40mg/kg) was significantly improved. Moreover, the selective 5-HT(2C) antagonist SB 242,084 (0.63, 2.5, and 10mg/kg) and melatonin (2.5, 10, and 40mg/kg) displayed also memory facilitating effects in both administration conditions. Finally, thioperamide used as positive reference compound to validate the experimental conditions, demonstrated a memory facilitating effect. In conclusion, agomelatine was shown to possess memory facilitating effects in the rat NOR task and both melatonergic agonist and 5-HT(2C) antagonist properties could be involved in these effects.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352847     DOI: 10.1016/j.pbb.2011.02.015

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  16 in total

1.  Ozone exposure of Flinders Sensitive Line rats is a rodent translational model of neurobiological oxidative stress with relevance for depression and antidepressant response.

Authors:  Mmalebuso L Mokoena; Brian H Harvey; Francois Viljoen; Susanna M Ellis; Christiaan B Brink
Journal:  Psychopharmacology (Berl)       Date:  2015-04-17       Impact factor: 4.530

2.  Beneficial Effect of Melatonin on Motor and Memory Disturbances in 6-OHDA-Lesioned Rats.

Authors:  Lyubka Tancheva; Maria Lazarova; Luciano Saso; Reni Kalfin; Miroslava Stefanova; Diamara Uzunova; Atanas G Atanasov
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

3.  Insomnia and dementia: is agomelatine treatment helpful? Case report and review of the literature.

Authors:  Vesile Altınyazar; Nefati Kiylioglu
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-16

4.  Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.

Authors:  Nataly Ladurelle; Cecilia Gabriel; Adela Viggiano; Elisabeth Mocaër; Etienne E Baulieu; Massimiliano Bianchi
Journal:  Psychopharmacology (Berl)       Date:  2011-12-08       Impact factor: 4.530

Review 5.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

6.  Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial.

Authors:  Yukihiko Shirayama; Michio Takahashi; Masatoshi Suzuki; Yoshiaki Tsuruoka; Koichi Sato
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

Review 7.  Melatonergic drugs in development.

Authors:  Alessia Carocci; Alessia Catalano; Maria Stefania Sinicropi
Journal:  Clin Pharmacol       Date:  2014-09-18

Review 8.  Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.

Authors:  Domenico De Berardis; Michele Fornaro; Nicola Serroni; Daniela Campanella; Gabriella Rapini; Luigi Olivieri; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Andrea De Bartolomeis; Alessandro Valchera; Giampaolo Perna; Monica Mazza; Marco Di Nicola; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

9.  Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.

Authors:  K Højgaard; S L Christiansen; E V Bouzinova; O Wiborg
Journal:  Psychopharmacology (Berl)       Date:  2017-11-19       Impact factor: 4.530

Review 10.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.